IP Library › Granted Patent US 8,440,794
Granted Patent B2
US 8,440,794 · App. 13/122,426 · Granted May 14, 2013

Peptide sequences, their branched form and use thereof for antimicrobial applications

Inventors: Luisa Bracci (Siena, IT); Chiara Falciani (Siena, IT); Alessandro Pini (Siena, IT)
Assignee: Universita' Degli Studi di Siena
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,794
App. No.
13/122,426
Granted
May 14, 2013
Kind
B2
Abstract

The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof.

Claims (22)

1. An antibacterial peptide consisting from the amino to the carboxylic terminal of an amino acid sequence selected from the group consisting of: KKIRVRLSA (SEQ ID NO. 1), RRIRVRLSA (SEQ ID NO. 2), KRIRVRLSA (SEQ ID NO. 3), and RKIRVRLSA (SEQ ID NO. 4).

2. The peptide according to claim 1 being of linear form.

3. The peptide according to claim 2 , multimerised on a skeleton of polyacrylamide, on a skeleton of dextrane units or on a skeleton of ethylene glycol units.

4. The peptide according to claim 1 , being in the form of Multiple Antigenic Peptides (MAP), having the following formula:

in which R is the peptide as claimed in claim 1 ; X is a trifunctional molecule; m=0 or 1; n=0 or 1; when m and n are 0 the peptide is a dimer; when m=1 and n=0 the peptide is a tetramer; when m=1 and n=1 the peptide is an octamer.

5. The MAP peptide according to claim 4 , wherein X is a trifunctional unit.

6. The MAP peptide according to claim 5 , wherein the trifunctional unit comprises at least two functional aminic groups.

7. The MAP peptide according to claim 6 , wherein X is lysine, ornithine, nor-lysine or amino alanine.

8. The MAP peptide according to claim 4 , wherein X is aspartic acid or glutamic acid.

9. The MAP peptide according to claim 4 , wherein X is propylene glycol, succinic acid, diisocyanates or diamines.

10. A method of treating bacterial infection in a subject in need thereof comprising,

administering to a subject suffering from a bacterial infection an effective amount of the peptide according to claim 1 , and

treating said subject.

11. A pharmaceutical composition comprising a pharmaceutically acceptable and effective quantity of the peptide according to claim 1 .

12. The pharmaceutical composition according to claim 11 , in the form of a solution to be injected in individuals for systemic use.

13. A method for neutralizing lipopolysaccharides in a subject in need thereof comprising

injecting an effective amount of a solution comprising the pharmaceutical composition according to claim 11 to a subject in need thereof.

14. The pharmaceutical composition according to claim 11 , in the form of eyewash, mouth wash, ointment, or solution for topic use.

15. A disinfectant or detergent preparation with antibacterial activity comprising the peptide according to claim 1 .

16. The method of claim 10 , comprising administering 25 mg/Kg in a single dose.

17. The method of claim 10 , comprising administering 10 mg/Kg in a single dose.

18. The method of claim 10 , comprising administering three doses of 5 mg/Kg every 12 hours.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2011
From: BRACCI, LUISA; FALCIANI, CHIARA; PINI, ALESSANDRO
To: UNIVERSITA' DEGLI STUDI DI SIENA
Reel/Frame 026067/0993 →
Continuity (2)
Provisional Application 61102854 · Oct 5, 2008
Related Publication 20110190198A1 · Aug 4, 2011